Scarica l'app Stockscreener
5.53
2.64%
-0.15
Dopo l'orario di chiusura:
5.52
-0.01
-0.18%
Replimune Group Inc Borsa (REPL) Ultime notizie
Kirby McInerney LLP Reminds Replimune Group, Inc. Investors - GlobeNewswire
Replimune (REPL) Faces Investor Lawsuit Following 77% Stock Crash After FDA Rejects Key DrugHagens Berman - GlobeNewswire
Shareholders of Replimune Group, Inc. (REPL): Protect Your Rights Before September 22, 2025Contact Levi & Korsinsky - ACCESS Newswire
How institutional ownership impacts Replimune Group Inc. stockMarket Trend Summary & Entry Point Confirmation Alerts - Newser
Replimune Group Inc. stock prediction for this week2025 Price Targets & Fast Entry High Yield Stock Tips - Newser
REPL LAWSUIT ALERT: Levi & Korsinsky Notifies Replimune Group, Inc. InvestorsLead Plaintiff Deadline September 22, 2025 - ACCESS Newswire
Applying big data sentiment scoring on Replimune Group Inc.2025 Dividend Review & Growth-Oriented Investment Plans - Newser
REPL STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Replimune Group, Inc. Investors with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Bragar Eagel & Squire, P.C. Reminds Investors of Class - GlobeNewswire
How hedge fund analytics apply to Replimune Group Inc. stockTrade Entry Summary & Fast Gaining Stock Strategy Reports - Newser
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Replimune Group, Inc. of Class Action Lawsuit and Upcoming DeadlinesREPL - WV News
Investors who lost money on Replimune Group, Inc.(REPL) - GlobeNewswire
Investors who lost money on Replimune Group, Inc.(REPL) should contact Levi & Korsinsky about pending Class Action - GlobeNewswire Inc.
ROSEN, THE FIRST FILING FIRM, Encourages Replimune Group, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – REPL - GlobeNewswire Inc.
Class Action Filed Against Replimune Group, Inc. (REPL) Seeking Recovery for InvestorsContact The Gross Law Firm - PR Newswire
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A - GlobeNewswire
Replimune Group, Inc. (REPL) Investors: September 22, 2025 Filing Deadline in Securities Class ActionContact Kessler Topaz Meltzer & Check, LLP - FinancialContent
Is Replimune Group Inc. a candidate for recovery playMarket Weekly Review & Safe Entry Momentum Tips - Newser
What moving averages say about Replimune Group Inc.Quarterly Portfolio Report & Trade Opportunity Analysis - Newser
The High Stakes of Biotech Litigation: Replimune's FDA Setback and Investor Recovery Pathways - AInvest
REPL Investors Have Opportunity to Lead Replimune Group, Inc. Securities Lawsuit First Filed by The Rosen Law Firm - PR Newswire
Shareholders that lost money on Replimune Group, Inc.(REPL) should contact Levi & Korsinsky about pending Class ActionREPL - WV News
Class Action Filed Against Replimune Group, Inc. (REPL) Seeking Recovery for Investors – Contact The Gross Law Firm - GlobeNewswire
REPL Investors Have the Opportunity to Lead the Replimune Securities Fraud Lawsuit with Faruqi & Faruqi, LLP - GlobeNewswire
Biotech Replimune Faces Derivative Suit Over Trial Claims - Law360
Investors SueWallSt as Replimune Group, Inc. Faces Securities Fraud Allegations - Nasdaq
Replimune (REPL) Faces Securities Class Action Following - GlobeNewswire
Did You Lose Money on Replimune Group, Inc. (REPL)? Levi & Korsinsky Urges Investors to Act Before September 22, 2025 - ACCESS Newswire
Will Replimune Group Inc. see short term momentum2025 Buyback Activity & Stepwise Entry and Exit Trade Signals - Newser
US Bancorp DE Buys 3,921 Shares of Replimune Group, Inc. $REPL - Defense World
Using R and stats models for Replimune Group Inc. forecasting2025 Market Overview & Risk Managed Investment Entry Signals - Newser
What technical models suggest about Replimune Group Inc.’s comebackEarnings Overview Report & AI Forecasted Entry and Exit Points - Newser
Applying chart zones and confluence areas to Replimune Group Inc.July 2025 Sector Moves & Fast Exit Strategy with Risk Control - Newser
Is Replimune Group Inc. stock reversal real or fakePortfolio Profit Report & Verified Momentum Stock Alerts - Newser
Replimune (REPL) Faces Securities Class Action Following Stock’s Collapse Amid FDA’s Rejection of Melanoma DrugHagens Berman - ACCESS Newswire
Investor Alert: Deadline Approaching to Join Replimune Group, Inc. (REPL) Class ActionContact Levi & Korsinsky - Newsfile
Shareholders of Replimune Group, Inc. Should Contact Levi & - GlobeNewswire
What earnings revisions data tells us about Replimune Group Inc.Weekly Profit Report & Community Trade Idea Sharing - Newser
Replimune Group Inc.’s volatility index tracking explainedMarket Volume Report & High Win Rate Trade Tips - Newser
Class Action Filed Against Replimune Group, Inc. (REPL)September 22, 2025 Deadline to JoinContact Levi & Korsinsky - MarketScreener
Lost Money on Replimune Group, Inc. (REPL)? Contact Levi & Korsinsky to Join Class Action Before September 22, 2025 - ACCESS Newswire
How to interpret RSI for Replimune Group Inc. stockEarnings Miss & Breakout Confirmation Alerts - Newser
Replimune Group, Inc. Class Action: The Gross Law Firm - GlobeNewswire
Time to SueWallSt? Levi & Korsinsky Files Lawsuit Over Replimune Group, Inc. Stock Losses - Stockhouse
Class Action Alert: Levi & Korsinsky Reminds Replimune Group, Inc. (REPL) Investors of September 22, 2025 Deadline - ACCESS Newswire
Class Action Lawsuit Filed Against Replimune Group, Inc. (REPL)Recover LossesContact Levi & Korsinsky Before September 22, 2025 - ACCESS Newswire
Contact The Gross Law Firm by September 22, 2025 Deadline to Join Class Action Against Replimune Group, Inc.(REPL) - PR Newswire
How to recover losses in Replimune Group Inc. stockPortfolio Risk Report & Free Long-Term Investment Growth Plans - Newser
REPL Investors Have Opportunity to Lead Replimune Group, Inc. Securities Fraud Lawsuit with the Schall Law Firm - PR Newswire
0.98%
8.06%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):